Who Paid My Doc
Hemal Nayak
Clinical Cardiac Electrophysiology San Antonio, TX Medical Doctor
NPI 1306892765 CMS profile 285624
8300 Floyd Curl Dr Fl 3, Fl 3, San Antonio, TX 78229
General payments
$285,130
Research payments
$150,000
Ownership & investment interest
$0
Research they led as principal investigator
$256,500
Through program year 2025, Hemal Nayak of San Antonio, TX is reported in the CMS Open Payments database as having received $285,130 across 709 general payments and $150,000 in research payments paid to them. Separately, studies naming them as principal investigator received $256,500 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 97th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $18,942 | 84 | |
| 2024 | General | $20,115 | 81 | |
| 2023 | General | $19,617 | 48 | |
| 2022 | General | $29,361 | 92 | |
| 2021 | General | $40,014 | 108 | |
| 2020 | General | $89,479 | 119 | |
| 2019 | General | $67,602 | 177 | |
| 2019 | Research | $150,000 | 1 |
Beside peers
- Hemal Nayak
- Clinical Cardiac Electrophysiology median
- Middle half of Clinical Cardiac Electrophysiology
- National median
In program year 2025, general payments to Hemal Nayak were reported at $18,942. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.
Show as a table
| Year | Hemal Nayak | Clinical Cardiac Electrophysiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $67,602 | $2,361 | $585–$8,260 | $163 |
| 2020 | $89,479 | $993 | $247–$4,351 | $114 |
| 2021 | $40,014 | $1,185 | $326–$4,739 | $132 |
| 2022 | $29,361 | $2,073 | $554–$6,789 | $149 |
| 2023 | $19,617 | $2,568 | $759–$8,159 | $160 |
| 2024 | $20,115 | $2,557 | $703–$7,403 | $164 |
| 2025 | $18,942 | $2,462 | $733–$7,710 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
454
Drug cost
$204,883
Branded share of claims
43.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 88 | $109,294 | |
| Xarelto Rivaroxaban | Brand | 50 | $60,205 | |
| Multaq Dronedarone Hcl | Brand | 19 | $29,559 | |
| Flecainide Acetate | Generic | 50 | $2,251 | |
| Metoprolol Succinate | Generic | 81 | $1,591 | |
| Amiodarone Hcl | Generic | 26 | $639 | |
| Sotalol Sotalol Hcl | Brand | 22 | $482 | |
| Metoprolol Tartrate | Generic | 39 | $277 | |
| Lisinopril | Generic | 16 | $204 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 20 | $196 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 68 billing codesPaid by Medicare
$73,466
Medicare patients
526
Services billed
1,030
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Atrial fibrillation | 53% | |
| Arthritis | 48% | |
| Ischemic heart disease | 46% | |
| Diabetes | 45% | |
| Heart failure | 43% | |
| Chronic kidney disease | 38% | |
| Depression | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
710 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Cardiac Electrophysiology in Texas
Michael Delaughter
Clinical Cardiac Electrophysiology · Bedford, TX
Andrea Natale
Clinical Cardiac Electrophysiology · Austin, TX
Jason Zagrodzky
Clinical Cardiac Electrophysiology · Austin, TX
Amin Al-Ahmad
Clinical Cardiac Electrophysiology · Austin, TX
Dale Yoo
Clinical Cardiac Electrophysiology · McKinney, TX
Rodney Horton
Clinical Cardiac Electrophysiology · Austin, TX
Related records
Clinical Cardiac Electrophysiology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Cardiac Electrophysiology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.